The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Charles River Laboratories International Inc

NYSE: CRL
Last

(U.S.) $80.54

Today's change-0.20 -0.25%
Updated January 13 4:02 PM EST. Delayed by at least 15 minutes.
 

Charles River Laboratories International Inc

NYSE: CRL
Last

(U.S.) $80.54

Today's change-0.20 -0.25%
Updated January 13 4:02 PM EST. Delayed by at least 15 minutes.

Charles River Laboratories International Inc crosses below 200-day moving average

Charles River Laboratories International Inc closed lower Friday, dropping (U.S.)$0.20 or 0.25% to (U.S.)$80.54 and crossing below its 200-day moving average. Shares have lost 0.36% for the last five days, but have gained 8.34% over the last 52 weeks. This security has underperformed the S&P 500 by 10.02% during the last year.

Key company metrics

  • Open(U.S.) $80.93
  • Previous close(U.S.) $80.74
  • High(U.S.) $81.46
  • Low(U.S.) $80.30
  • Bid / Ask-- / --
  • YTD % change+5.71%
  • Volume288,957
  • Average volume (10-day)448,295
  • Average volume (1-month)459,050
  • Average volume (3-month)469,914
  • 52-week range(U.S.) $65.70 to (U.S.) $89.18
  • Beta0.99
  • Trailing P/E27.03×
  • P/E 1 year forward18.04×
  • Forward PEG1.42×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.98
Updated January 13 4:02 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+9.19%

Based on its net profit margin of 9.19%, Charles River Laboratories International Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.12%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 24, 201609/24/2016Jun 25, 201606/25/2016Mar 26, 201603/26/2016Dec 26, 201512/26/2015
Revenue426434355354
Total other revenue--------
Total revenue426434355354
Gross profit156170141141
Total cost of revenue269264214213
Total operating expense367376303302
Selling / general / administrative861008381
Research & development--------
Depreciation / amortization121167
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income59585152
Interest income (expense), net non-operating-7-9-4-4
Gain (loss) on sale of assets--------
Other--------
Income before tax53545250
Income after tax38363833
Income tax, total16191417
Net income38353732
Total adjustments to net income--------
Net income before extra. items37353733
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items37353733
Inc. avail. to common incl. extra. items38353732
Diluted net income38353732
Dilution adjustment------0
Diluted weighted average shares48484848
Diluted EPS excluding extraordinary itemsvalue per share0.780.730.780.69
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share0.780.730.780.69